Workflow
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

—Q3 2025 ORLADEYO net revenue of 159.1million(+37percentyoy)——Q32025operatingprofitof159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of 29.6 million (+285 percent y-o-y); non-GAAP operating profit of 51.7million(+107percentyoy);continuedimprovementinnonGAAPoperatingprofitmarginfromstrongoperatingleverage——ORLADEYOFY2025revenueguidanceraisedtobetween51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between 590 to 600million;FY2025nonGAAPoperatingexpenseguidanceloweredtobetween600 million; FY 2025 non-GAAP operating expense guidance lowered to between 430 to $440 million— —Sale of European ORLADEYO business completed; proceeds used ...